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Background: Myocardial infarction (MI) is the major cause of death by disease in the world. Many studies
have identiﬁed the associations between matrix metalloproteinase 9 (MMP9) C-1562T polymorphismsKey words:
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and MI. However, the results remain inconclusive. To clarify the role of MMP9 C-1562T polymorphism in
MI risk, we conducted a systematic review and large-scale meta-analysis.
Methods: Studies published between January 2005 and March 2014 were obtained from the electronic
databases PubMed, Medline, and Embase. The odds ratios (ORs) with 95% CIs were calculated for
comparisons of the alleles and genotypes in the overall population and in ethnicity subgroups to
measure the strength of genetic associations.
Results: A total of 7 related studies, including 3952 MI cases and 4977 healthy control subjects were
included in our meta-analysis. Our results show a statistically signiﬁcant association between T allele and
MI in the overall population (OR ¼ 1.23; 95% CI, 1.02–1.48; P ¼ 0.03). The risk of MI was also signiﬁcantly
higher in patients carrying the T allele (TC þ TT genotypes) than in those with the CC genotype (P o 0.05).
In stratiﬁed analysis by ethnicity, we found the T allele was strongly associated with MI in white
populations, whereas in Asian populations there appeared no signiﬁcant association.
Conclusions: Our data show that the MMP9 C-1562T polymorphism is a risk factor associated with
increased MI susceptibility in the total population and white populations, although no signiﬁcant
association was observed in Asians populations. Further studies with larger sample sizes and assessing
gene–gene and gene–environment interactions are required.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Myocardial infarction (MI) is a leading cause of morbidity and
mortality worldwide. It is an extreme manifestation of coronary
artery disease. Approximately 90% of all cases of MI are the result
of acute occlusive thrombus due to a ruptured coronary artery
atheromatous plaque.1 New myocardial ischemia occurs in 54% of
patients within the ﬁrst year after MI and 1-year risk of reinfarc-
tion presents in 17.4% of patients with MI.2,3 The American Heart
Association reports that approximately 600,000 new patients
sustain an MI and 320,000 patients have an episode of recurrent
MI each year in the United States.4 Despite the available thera-
peutic approaches, MI is still associated with high rates of acute
death and long-term complications such as heart failure. Its
physiopathology is complex, and several inherited and acquiredInc. This is an open access article u
D, Department of Cardiovas-
ng Zhou University, Zhengz-
-Guo).risk factors that predispose to the development of atherosclerotic
lesions and plaque rupture are involved.
Matrix metalloproteases (MMPs) are a family of Zn2þ-depend-
ent enzymes with proteolytic activity against connective tissue
proteins that play important roles in the development and
progression of atherosclerotic lesions.5–7 They are involved in
degradation of the extracellular matrix, weakening of the ﬁbrous
cap, and subsequently destabilization of atherosclerotic lesions.8,9
MMP-9, also known as gelatinase B or 92-kDa type IV collagenase,
is 1 member of the MMP family and is an enzyme in human beings
that is encoded by theMMP9 gene. It plays an important role in the
distant metastatic potential of cancer cells for its collagenolytic
activity that is known to be associated with the disruption of
basement membrane.10 MMP9 is highly expressed in the vulner-
able regions of atherosclerotic plaques and has been suggested to
be causally involved in plaque rupture.11 Dysregulation of MMP9
expression is a characteristic of several pathologic conditions,
including metastasis, vascular and cardiac remodeling, atheroscler-
otic plaque rupture, and acute coronary syndrome.12 Studies have
indicated that higher plasma concentrations of MMP9 may be ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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concentrations are elevated in patients with acute MI.14 The
MMP9 gene C-1562T (rs3918242) polymorphism (C-T) in the
promoter region abolishes the DNA-protein interaction, resulting
in higher activity of the T-allelic promoter.15 This polymorphic site
has a close association with susceptibility to coronary atheroscle-
rosis and subsequent acute coronary syndromes, and inﬂuences
critical steps in the binding of transcription factors or the overall
efﬁciency of transcription.15,16
Although numerous reports have identiﬁed the association of
MMP9 C-1562T polymorphism and MI risk, inconsistency has been
presented for different allele frequencies among study popula-
tions. The purpose of conducting this meta-analysis was to clarify
and quantify the overall risk of MMP9 C-1562T polymorphism on
developing MI.Materials and Methods
Identiﬁcation and eligibility of relevant studies
A comprehensive literature search was conducted using the
electronic databases PubMed, Medline, and Embase for relevant
articles published between January 2005 and March 2014. The key
words matrix metalloproteinase 9 or MMP9 or gelatinase B, poly-
morphism ormutation or variant, andmyocardial infarction or ischemic
cardiovascular disease as well as their combinations were used. All
studies matching the eligibility criteria were retrieved, and references
were checked for other relevant publications. The language was
limited to English only. The search was focused on studies that had
been conducted in human beings. Only full-text articles and the most
recent studies were included in our meta-analysis.
Criteria for inclusion
Studies eligible for inclusion in our meta-analysis must have met
the following criteria: case-control or cohort study; MI events were
conﬁrmed by reviewing symptoms, cardiac enzymes, and ECG ﬁnd-
ings according to the guidelines17 and the controls should be the
healthy age- and sex-matched persons; only MI as the study outcome
and the polymorphism site should be C-1562T; the results were exp-
ressed as odds ratio (OR) and corresponding 95% CI; the distribution of
genotype in MI and control groups were available; and genotype
distribution of control must be in Hardy-Weinberg equilibrium.7 references included in the meta-analysis
53
70 abstracts screened
27 
97 references initially identified
Exc
Not
Wit
17 full-text articles comprehensively assessed
against inclusion criteria
Figure 1. Flow chart of the liteQuality assessment and data extraction
Two investigators independently extracted data and reached
consensus on all of the items. Any disagreement was resolved by
discussing with the third expert. Data retrieved from the reports
included ﬁrst author, publication year, demographics, total num-
bers of cases and controls, and genotype distribution of MMP9
C-1562T polymorphism in cases and controls.
Statistical analysis
The overall association between MMP9 C-1562T polymorphism
and MI was measured by ORs and 95% CI, which were calculated
according to the method of Woolf.18 The signiﬁcance of the pooled
ORs was determined by the Z test, and a P value o 0.05 was
considered statistically signiﬁcant. The allelic model (T vs C) and
genetic models (dominant effect: TT þ TC vs CC and CC vs TT þ TC)
were examined to evaluate the C-1562T allele and the risk of MI. The
I2 test was used to assess the proportion of statistical heterogeneity
and the Q statistic test was used to deﬁne the degree of
heterogeneity. A P value o 0.10 for the Q test and I2 o 50%
was considered signiﬁcant among the studies. Data were com-
bined using both a ﬁxed-effects model (the inverse variance-
weighted method) and a random effects model (DerSimonian
and Laird method).19,20 The ﬁxed-effects model is used when
the effects are assumed to be homogenous, whereas the
random effects model is used when they are heterogenous. The
evidence of publication bias was assessed by visual funnel plot
inspection.
To assess if our results were substantially inﬂuenced by the
presence of any individual study, we conducted a sensitivity
analysis by systematically removing each study and recalculating
the signiﬁcance of the result. Statistical analyses were conducted
in Review Manager (version 5.2, The Cochrane Collaboration,
Oxford, United Kingdom). All tests were 2-sided.Results
Study selection and characteristics
The literature search identiﬁed 97 articles. Of those, 27 records
were excluded after title review and 70 articles were left for
further review. After abstracts were screened for relevance, 53 records excluded at abstract review
records excluded after title review
luded:
 include control group not healthy control (n = 6)
hout genotype distribution (n = 4)
rature screening process.
Table I
Main characteristics of included studies in the meta-analysis
First author Year of
Publication
Country Ethnicity Total
cases
Total
controls
Genotyping
method
Haberbosch24 2005 Germany White 1280 535 PCR-RFLP
Nuzzo27 2006 Italy White 115 123 PCR-RFLP
Horne25 2007 United
States
White 1693 3455 Taqman
Koh22 2008 Korea Asian 206 173 PCR-RFLP
Ghaderian21 2010 Iran Asian 234 200 Taqman
Wang23 2012 China Asian 384 451 PCR-RFLP
Sewelam26 2013 Egyptian White 40 40 RFLP
PCR-RFLP ¼ polymerase chain reaction-restriction fragment length polymorphism.
Table II
Distributions of matrix metalloproteinase 9 C-1562T polymorphisms genotypes
and alleles among patients and controls
First author Cases Controls
TT,
n
TC,
n
CC,
n
T-frequency,
%
TT,
n
TC,
n
CC,
n
T-frequency,
%
Haberbosch24 21 293 966 13.1 12 109 414 12.4
Nuzzo27 3 39 73 19.6 1 36 86 15.4
Horne25 34 440 1219 15.0 69 795 2591 13.5
Koh22 4 51 151 14.3 0 31 142 9.0
Ghaderian21 10 47 177 14.3 6 53 141 16.3
Wang23 11 87 286 14.2 6 72 373 9.3
Sewelam26 1 7 32 11.3 0 0 40 0
Z. Juan et al. / Current Therapeutic Research 77 (2015) 40–4542additional articles were excluded and 17 full-text articles were
comprehensively assessed against the inclusion criteria. Overall,
the initial search with the key words and the subject terms
identiﬁed 7 articles that met the inclusion criteria and were
eligible for review. Figure 1 shows the study inclusion/exclusion
process.
Of the 7 reports focusing on the relationship between MMP9
polymorphism and MI, 3 were conducted in Asian popula-
tions,21–23 whereas 4 were in white populations.24–27 A total of
3952 MI cases and 4977 healthy controls were included. The
distribution of the genotypes in the control group was consistent
with Hardy-Weinberg equilibrium. The detailed characte-
ristics of the included studies are shown in Table I. The
distributions of genotypes in the individual studies are pre-
sented in Table II.
Association between MMP9 polymorphism and MI among the total
population
Table III shows the meta-analysis of the MMP9 C-1562T poly-
morphism under various genetic models. The heterogeneity
between studies was assessed and the ﬁxed-effect model or the
random-effect model was employed for calculating the pooled OR.
Overall, our results showed that the frequency of the T allele is
higher in persons with a history of MI than in healthy controls
(14.3% vs 12.9%), and demonstrated statistically signiﬁcant positive
association between the risk factor T allele and MI in the overall
population (OR ¼ 1.23; 95% CI, 1.02–1.48; P ¼ 0.03) in a random-
effect model, as shown in Figure 2. The risk of MI was also
signiﬁcantly higher in patients carrying the T allele (TC þ TT
genotypes) than in those with the CC genotype (OR ¼ 1.24; 95% CI,
1.01–1.51; P ¼ 0.04). Furthermore, as shown in Figure 3, the
CC genotype signiﬁcantly increased the risk of MI (CC vs TC þ TT:
OR ¼ 0.81; 95% CI, 0.66–0.99; P ¼ 0.04).
Stratiﬁed analysis by ethnicity
Various genetic models were examined under stratiﬁed analy-
sis by ethnicity, as shown in Table III. In white populations, the
frequency of the T allele is higher in persons with a history of MITable III
Comparison of matrix metalloproteinase genotypes in the total, Asian, and white popul
Genotype Total Asian
OR (95% CI) P Ph/I2 OR (95% CI
T versus C 1.23 (1.02–1.48) 0.03 0.02/59 1.33 (0.86–
TT þ TC versus CC 1.24 (1.01–1.51) 0.04 0.03/56 1.28 (0.78–
CC versus TC þ TT 0.81 (0.66–0.99) 0.04 0.03/56 0.78 (0.47–
OR ¼ odds ratio; Ph ¼ p value for heterogeneity.than in healthy controls (26.8% vs 24.6%), and our results showed a
statistically signiﬁcant association between T allele and MI risk (OR
¼ 1.14; 95% CI, 1.03–1.26; P ¼ 0.01) in a ﬁxed-effect model.
Moreover, presence of the T allele (TC þ TT) had a more signiﬁcant
relationship with MI risk than in controls when comparing with
the CC genotype (TC þ TT vs CC: OR ¼ 1.17; 95% CI, 1.05–1.31; P ¼
0.005). The CC genotype also signiﬁcantly increased the risk of MI
(CC vs TC þ TT: OR ¼ 0.85; 95% CI ¼ 0.76–0.95; P ¼ 0.005) in a
ﬁxed-effect model. However, in Asian populations, no signiﬁcant
association was found between allelic model and genetic models
(T vs C: OR ¼ 1.33; 95% CI, 0.86–2.03; P ¼ 0.20; TT þ TC vs CC: OR
¼ 1.28; 95% CI, 0.78–2.11; P ¼ 0.33; CC vs TC þ TT: OR ¼ 0.78; 95%
CI, 0.47–1.28; P ¼ 0.33) in a random-effect model. There was no
heterogeneity between these 2 subgroups (P ¼ 0.75; I2 ¼ 0%), as
shown in Figure 4.
Sensitivity analyses and publication bias
A single study included in the meta-analysis was deleted each
time to reﬂect the inﬂuence of the individual data set to the pooled
ORs, and the corresponding pooled ORs were not materially
changed. This procedure conﬁrmed the stability of our overall
result.
Begger’s funnel plot was conducted to assess the publication
bias of the literature. The shape of funnel plots did not reveal any
evidence of funnel plot asymmetry (as shown in Figure 5). Thus
there was no possibility of publication bias risk in the meta-
analysis.Discussion
We found that the frequency of T alleles is higher in patients
with a history of MI than in healthy controls and demonstrated a
statistically signiﬁcant strong association between the risk factor T
allele and MI risk in the overall human population and in white
populations (P o 0.05). The risk of MI was also signiﬁcantly higher
in patients carrying the T allele (TC þ TT genotypes) than in those
with the CC genotype. However, in Asian populations, no signiﬁ-
cant association appeared. Overall, we found a signiﬁcantation among patients with a history of myocardial infarction and healthy controls
White
) P Ph/I2 OR (95% CI) P Ph/I2
2.03) 0.20 0.02/75 1.14 (1.03–1.26) 0.01 0.18/38
2.11) 0.33 0.01/77 1.17 (1.05–1.31) 0.005 0.23/30
1.28) 0.33 0.01/77 0.85 (0.76–0.95) 0.005 0.23/30
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Figure 2. Forest plot of association between C-1562T polymorphism and myocardial infarction (T vs C allele). M-H ¼ Mantel-Haenszel.
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overall human population and white populations. Our results were
consistent with a previous meta-analysis conducted by Wang
et al.28 Their analysis included 7 articles published between 1999
and 2010, including 4473 cases and 3343 healthy controls, and the
result demonstrated signiﬁcant associations between this poly-
morphism and MI risk. However a subsequent meta-analysis
identiﬁed that MMP9 C-1562T was signiﬁcantly associated with
MI in East Asians, whereas no signiﬁcant association was observed
in Western populations.29 Our study is an update analysis of MMP
C-1562T polymorphism with the risk of MI.
The human MMP9 gene is located on chromosome 20q12.2-13.1,
and is functionally implicated in the process of infarct healing. A
number ofMMP9 single nucleotide polymorphisms in the promoter,
coding, and untranslated regions have been reported.30 Among
them, promoter C-1562T polymorphism with a cytosine to thymi-
dine transition is the most studied and functional studies indicate
that this polymorphism has an allele-speciﬁc effect on MMP-9
transcription.13 The variant T allele of MMP-9 C-1562T polymor-
phism has been associated with an increase in expression of the
gene and higher MMP9 levels, due to preferential binding of the
transcriptional repressor protein to the C allele (binding weaker to
the T allele), and overexpression of MMP9 was found in human
atherosclerotic plaques and involved in rupture of the plaques.31,32
Zhang et al15 revealed that the sequence between nucleotide
position –1567 and –1559 relative to the transcription start site of
the MMP9 gene, which encompasses the –1562 polymorphic site,
can interact with a nuclear protein whose entity is still unknown.
Clinical studies have also established a relationship between MMP9
and post-MI remodeling and mortality, making MMP-9 a viable
candidate to add to the multiple biomarker list.33 It is thereforeHaberbosch
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Figure 3. Forest plot of association between the C-1562T polymorphism and myocardialpossible that the expression level associated with this polymor-
phism affects the activity of this enzyme.34
Few epidemiologic studies have investigated associations
between MMP9 and MI onset. Setianto et al35 demonstrated that
the MMP9 C-1562T polymorphism is associated with high serum
MMP9 levels in patients with segment elevation MI. Hansson
et al36 found that serum MMP9 and tissue inhibitor of
metalloproteinases-1 levels were related to mortality risk of MI.
Jefferis et al37 identiﬁed that serum MMP9 is univariately associ-
ated with risk of MI and stroke. Rodius et al38 indicate that the
MMP9 polymorphism does not seem to be associated with clinical
outcome and in particular with the development of left ventricular
dysfunction and heart failure.
Thrombosis is generally accepted as the most common patho-
genetic pathway of MI. It has been reported that MMP9 brings
about destabilizing structural changes in vulnerable atheroscler-
otic plaques.39 MMP9 also potentiates the chemokine interleukin-8
and modiﬁes the local chemokine proﬁle,40 and hence may
promote cellular inﬁltration of plaques, weakening the ﬁbrous
cap of the atherosclerotic plaque, and increasing the size of the
lipid core. These processes render the plaque susceptible to
rupture due to reduced mechanical strength and hence increase
the probability of atherothrombotic ischemia. It has been identi-
ﬁed that MMP9 is present in the early stages of atherosclerotic
plaque formation,41 having a protective role against its rupture.42
Neutrophils, macrophages, and lymphocytes are cell sources of
MMP9. MMP-9 expressed in post-MI cardiac remodeling, and
clinical studies showed that MMP-9 is a biomarker for cardiac
remodeling and predicted adverse left ventricular remodeling
after MI.43 Structural details about the ﬂexibility of MMP-9 mono-
mers show that it may be viewed as a multidomain enzyme in0.90 [0.71, 1.14]
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Figure 4. Odds ratios of myocardial infarction (with 95% CIs) in T allele carriers (CT and TT genotype) of matrix metalloproteinase 9 C-1562T polymorphism versus CC
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Z. Juan et al. / Current Therapeutic Research 77 (2015) 40–4544which the hemopexin, the O-glycosylation, and the catalytic
domains yield support for attachment, articulation, and catalysis,
respectively.
Several limitations are present in our meta-analysis. First, the
MMP9 polymorphism may interact with other known and
unknown risk factors relating to MI that should be considered,
such as hypertension, diabetes, dyslipidemia, and prior coronary
artery disease. Second, 3 relevant articles were excluded because
we could not obtain sufﬁcient information to calculate the geno-
type distribution.35,44,45 Third, sample sizes of several studies were
too small, and studies in other languages were not retrieved.
Fourth, additional analysis taking into account sex and information
of MI should be conducted to give a new insight into the role of the
studied polymorphism in the development of MI in various
populations.Conclusions
Our meta-analysis suggests a role of MMP9 C-1562T polymor-
phisms in the occurrence of MI. This polymorphism is signiﬁcantlySE(log[OR])0
0.5
1
1.5
2
0.01 0.1 1 10 100
OR
Figure 5. Begg’s funnel plot analysis of publication bias for myocardial infarction.
OR ¼ odds ratio.associated with MI in white populations, although no signiﬁcant
association was observed in Asians populations. Further studies
with larger sample size and assessing gene–gene and gene–
environment interactions are required. Meanwhile, race selection
should be paid more attention because the pathogenesis of a
disease might have a different basis in different racial population
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